Is the Major Depressive Disorder a predictor to transition to psychosis in a child and adolescent sample of Psychosis Risk Syndrome?
Poster C123, Saturday, October 22, 11:30 am - 1:00 pm, Le Baron
Marta Rodríguez1, Xavier Alvarez1, Jordina Tor2, Marta Pardo1, Daniel Muñoz1, Anna Sintes1, Marta Espadas1, Elena de la Serna3, Inmaculada Baeza3, Gisela Sugranyes3, Montserrat Dolz1; 1Hospital Sant Joan de Déu, 2Fundació Sant Joan de Déu, 3Hospital Clínic de Barcelona
Purpose: The aim of this study is to describe and determine the prevalence of major depressive disorder and their impact on psychosis transition in Psychosis Risk Syndrome (PRS) subjects in a child and adolescent sample. Method: A prospective longitudinal and multisite study, which evaluate the clinical, cognitive and neuroimaging results of patients with PRS compared with a control group. Inclusion criteria for PRS patients are: age between 10 and 17 years, one or more of the criteria for PRS, as assessed by the Structural Interview for Prodromal Syndromes (SIPS) interview, no diagnosis of psychotic disorder, autism spectrum disorder, neurological disease and / or mental retardation. Subjects are assessed by the Kiddie-Sadds Scale (K-SADS-PL), the Hamilton Depression Rating Scale (HDRS) and the SIPS. Data analysis is performed by SPSS 20.0 statistic program. Results: In our sample we have a total of 95 PRS subjects, 43% of them have a diagnosis of an affective disorder and a 30’5% major depressive disorder (MDD), being the most prevalent. Transition rate to psychosis of the MDD subjects has been 27’6%. We evaluate the difference in SOPS items between both groups (transitioned versus non-transitioned): we have found statistically significant differences in Total positive attenuated symptoms (p=0’046) and P1 (Unusual Thought Content/Delusional Ideas) (p=0’004). Conclusion: Results show that the MDD subjects who have transitioned to psychosis, suffer more positive symptoms, especially unusual thought content or delusional ideas, without differences in negative symptoms.
Topic Area: Ultra High Risk / Prodromal Research